Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine 10-day versus 3+7 chemotherapy in older newly diagnosed AML
NL-OMON44877Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of decitabine and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started Dec 2014; status: recruiting.
02
Drugs
decitabinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON44877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44877.